HLA-DR and -DQ alleles in Italian patients with melanoma

Tissue Antigens

Volumn 51, Issue 3, 1998, Pages 276-280

  Lulli, P ^a,c   Grammatico, P ^a   Brioli, G ^a   Catricala C ^b   Morellini, M ^a   Roccella, M ^a   Mariani, B ^a   Pennesi, G ^a   Roccella, F ^a   Cappellacci, S ^a   Trabace, S ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

DQB haplotype; HLA class II; HLA DQ3; Melanoma

Indexed keywords

HLA ANTIGEN CLASS 2; HLA DQ ANTIGEN; HLA DR ANTIGEN; PRIMER DNA;

ALLELE; ARTICLE; CONTROLLED STUDY; HAPLOTYPE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MELANOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 6844265573     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0039.1998.tb03102.x     Document Type: Article

References (19)

1. Cabrera T, Ruiz-Cabello F, Garrido F. Biological implications of HLA-DR expression in tumours. Scand J Immunol 1995: 41: 398-406.
2. Bouwes Bavinck JN, Claas FHJ. The role of HLA molecules in the development of skin cancer. Hum Immunol 1994: 41: 173-179.
3. Le Poole C, Mutis T, van den Wijngaard RMJGJ et al. A novel, antigen-presenting function of melanocytes and its possible relationship to hypopigmentary disorders. J Immunol 1993: 15: 7284-7292.
4. Barger BO, Acton RT, Soong SJ, Roseman J, Balch C. Increase of HLA-DR4 in melanoma patients from Alabama. Cancer Res 1982: 42: 4276-4279.
5. Mueller-Eckhardt G, Sehendel DJ, Hundeiker M et al. Possible association between HLA-DR5 and superficial spreading melanoma (SSM). Int J Cancer 1984: 34: 751-755.
6. Marincola FM, Venzon D, White D et al. HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy. Cancer Res 1992: 52: 6561-6566.
7. Muto M, Ohmura A, Nakano J et al. HLA class I polymorphism and the susceptibility to malignant melanoma. Tissue Antigens 1996: 47: 447-449.
8. Lee JE, Reveille JD, Ross MI, Platsoucas DC. HLA-DQB1*0301 association with increased cutaneous melanoma risk. Int J Cancer 1994: 59: 510-513.
9. Lee JE, Loflin PT, Laud PR, Lu M, Reveille JD, Lawlor DA. The human leukocyte antigen TAP2 gene defines the centromeric limit of melanoma susceptibility on chromosome 6p. Tissue Antigens 1996: 47: 117-121.
10. Terasaki PI, Bernoco D, Park MS, Ozturk G, Iwaky Y. Microdroplet testing for HLA-A,B,C and DR antigens. Am J Clin Pathol 1978: 69: 103-120.
11. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992: 39: 225-235.
12. Olerup O, Aldener A, Fogdell A. HLA-DQBI and HLA-DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. Tissue Antigens 1993: 41: 119-134.
13. Fernandez-Vina MA, Gao X, Moraes ME et al. Alleles at four HLA class II loci determined by oligonucleotide hybridization and their associations in five ethnic groups. Immunogenetics 1991: 34: 299-312.
14. Matullo G, Griffo MR, D'Alfonso S. Population genetics of HLA genes. Minerva Biotecnol 1994: 6: 253-268.
15. Boon T, Gajewski FT, Coulie PG. From defined human tumor antigens to effective immunization? Immunol Today 1995: 16: 334-336.
16. Allen M, Kalantari M, Ylitalo N et al. HLA DQ-DR haplotype and susceptibility to cervical carcinoma: indications of increased risk for development of cervical carcinoma in individuals infected with HPV 18. Tissue Antigens 1996: 48: 32-37.
17. Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: Tsuji K, Aizawa M, Sasazuki T, ed. HLA 1991. Proceedings of the Eleventh International Histocompatibility Workshop and Conference. Vol. 1. Oxford: Oxford University Press, 1992: 1065-1220.
18. Compston DAS. HLA and neurological disease. Neurology 1978: 28: 413-414.
19. Olsen AC, Possum B, Kirkin AF, Zeuthen J, Gaudernack G. A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses. Scand J Immunol 1995: 41: 357-364.